AIRNA

Executive Summary

AIRNA is a German biotechnology company founded in 2021, headquartered in Hamburg with operations in Tübingen and Cambridge, MA. The company is pioneering RNA editing therapeutics to deliver functional cures for both rare and common diseases, leveraging genetic advances to develop precise medicines. As a private, early-stage company, AIRNA's platform focuses on editing RNA to correct disease-causing mutations without altering the genome, offering potential advantages in safety and reversibility. While the company has not disclosed specific pipeline programs or financing details, its approach positions it in the competitive RNA therapeutics landscape. With a strong scientific foundation and presence in key biotech hubs, AIRNA aims to advance its lead programs toward clinical development. The company's success will depend on preclinical validation, securing partnerships or funding, and demonstrating its editing technology's efficacy in vivo. Given its early stage, near-term milestones are likely centered on lead candidate selection and IND-enabling studies.

Upcoming Catalysts (preview)

• Q4 2026Lead Program IND Filing40% success
• Q3 2026Series A or B Financing Round70% success
• Q2 2027Strategic Partnership for RNA Editing Platform50% success